Adial Pharmaceuticals (NASDAQ: ADIL) furnishes Q2 2025 earnings press release

Rhea-AI Filing Summary

Adial Pharmaceuticals, Inc. furnished an update on its financial results by issuing a press release that includes financial information for the fiscal quarter ended June 30, 2025. The company submitted this press release as Exhibit 99.1 to a current report on Form 8-K.

The company states that the press release and related Item 2.02 information are being furnished rather than filed, meaning they are not subject to certain liability provisions of the federal securities laws and will not automatically be incorporated by reference into other SEC filings.

false 0001513525 0001513525 2025-08-14 2025-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 14, 2025

Adial Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)

Delaware		001-38323		82-3074668
(State or other jurisdiction  of incorporation)		(Commission File Number)		(IRS Employer  Identification No.)

4870 Sadler Road, Suite 300
Glen Allen, VA 23060

(Address of principal executive offices and zip code)

(804) 487-8196

(Registrant’s telephone number including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbols		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ADIL		The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2025, Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the fiscal quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are furnished with this Current Report on Form 8-K:

Exhibit Number		Exhibit Description
99.1		Press Release, issued by Adial Pharmaceuticals, Inc. on August 14, 2025
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 14, 2025	ADIAL PHARMACEUTICALS, INC.
	By:	/s/ Cary J. Claiborne
	Name:	Cary J. Claiborne
	Title:	President and Chief Executive Officer

2

FAQ

What did Adial Pharmaceuticals (ADIL) disclose in this 8-K filing?

Adial Pharmaceuticals furnished a Form 8-K to provide a press release containing financial information for the fiscal quarter ended June 30, 2025, which is attached as Exhibit 99.1.

Which period do the Adial Pharmaceuticals (ADIL) results in the press release cover?

The press release attached to the filing contains financial information for Adial Pharmaceuticals’ fiscal quarter ended June 30, 2025.

Is the Adial Pharmaceuticals (ADIL) earnings press release considered filed with the SEC?

No. The company states that the information in Item 2.02 and the Exhibit 99.1 press release is furnished, not filed, and is not subject to Section 18 liability or automatically incorporated into other SEC filings.

What exhibits are included in this Adial Pharmaceuticals (ADIL) 8-K?

The filing includes Exhibit 99.1, a press release issued on August 14, 2025, and Exhibit 104, the cover page interactive data file.

Who signed the Adial Pharmaceuticals (ADIL) Form 8-K?

The Form 8-K was signed on behalf of Adial Pharmaceuticals, Inc. by Cary J. Claiborne, President and Chief Executive Officer.

On what date did Adial Pharmaceuticals (ADIL) issue the press release referenced in the 8-K?

Adial Pharmaceuticals issued the referenced press release on August 14, 2025, the same date as the Form 8-K report.